16 completed, 5 terminated, 4 unknown. 11 Phase 4, 4 Phase 3, 2 Not applicable, 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 11 | Completed 5, Terminated 4, Unknown 2 |
| Phase 3 | 4 | Completed 3, Terminated 1 |
| Not applicable | 2 | Completed 1, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow HIV-Associated Lipodystrophy Syndrome: new trials by email Literature Review of HIV-Associated Lipodystrophy Syndrome trials Research Report on HIV-Associated Lipodystrophy Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Visceral Adiposity Measurement and Observation Study Diagnostic Test, HIV Anti-retroviral Background Therapy - HIV, HIV-Infections | Completed | Theratechnologies | 196 | 2022-04-18 | 2023-11-18 | |
| Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI MRI - HIV I Infection, HIV Associated Lipodystrophy | Not applicable | Unknown | University of Novi Sad | 120 | 2021-05-01 | 2021-12-01 |
| Contribution of Dolutegravir to Obesity and Cardiovascular Disease Dolutegravir 50 MG, Antiretroviral/Anti HIV - HIV-1-infection, Antiviral Drug Adverse Reaction | Phase 4 | Completed | Augusta University | 10 | 2020-09-17 | 2023-07-27 |
| Body Composition and Adipose Tissue in HIV Tesamorelin - HIV Lipodystrophy Syndrome, Growth Hormone Deficiency | Phase 4 | Terminated | Columbia University | 6 | 2018-02-07 | 2026-05-19 |
| Detraining in People Living With HIV/AIDS combined training - Lipodystrophy Syndrome, HIV, Sarcopenia | Not applicable | Completed | Universidade Federal do Rio Grande do Norte | 2 | 2016-02-19 | 2017-03-09 |
| An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo - HIV-associated Lipodystrophy Syndrome | Phase 1 | Completed | ViiV Healthcare | 16 | 2013-05-01 | 2013-11-04 |
| Energy Expenditure of People Living With HIV/AIDS use of lipid-lowering drugs. - HIV/AIDS, HIV Lipodystrophy Syndrome | Completed | University of Sao Paulo General Hospital | 45 | 2013-03-01 | 2015-08-21 | |
| Follow-up on the HIGH: Low Study - the Longterm Effects of Growth Hormone HIV Infections, HIV-Associated Lipodystrophy Syndrome | Unknown | Hvidovre University Hospital | 46 | 2008-05-01 | 2008-04-21 | |
| TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy Tesamorelin, Placebo for Tesamorelin - Lipodystrophy, HIV Infections | Phase 3 | Completed | Theratechnologies | 263 | 2007-08-01 | 2022-09-30 |
| Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE Newfill, Eutrophill - HIV-Associated Lipodystrophy Syndrome | Phase 3 | Completed | French National Agency for Research on AIDS and Viral Hepatitis | 148 | 2006-12-01 | 2011-12-22 |
| Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome HIV-Associated Lipodystrophy Syndrome | Completed | NHS Lothian | 50 | 2006-08-01 | 2011-06-13 | |
| Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy poly-L-lactic acid - HIV-Associated Lipodystrophy, HIV Infections | Phase 4 | Terminated | Kirby Institute | 100 | 2005-11-01 | 2009-04-02 |
| Polyacrylamide Hydrogel Injection in HIV-related Lipoatrophy Eutrophill - HIV Infection, Antiretroviral Side Effects | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 100 | 2005-11-01 | 2010-03-01 |
| Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs), continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs) - HIV-Associated Lipodystrophy Syndrome | Phase 4 | Completed | Bristol-Myers Squibb | 219 | 2005-07-01 | 2010-05-07 |
| Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance Rosiglitazone, Recombinant human growth hormone + rosiglitazone - HIV-Associated Lipodystrophy Syndrome, Insulin Resistance | Phase 1 / Phase 2 | Completed | Weill Medical College of Cornell University | 77 | 2005-03-01 | 2014-02-13 |
| Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Different HAART regimens - HIV Associated Lipodystrophy Syndrome., HIV | Phase 4 | Completed | Danish HIV Research Group | 100 | 2004-03-01 | 2005-09-05 |
| Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitor - HIV Infections, HIV-Associated Lipodystrophy Syndrome | Phase 4 | Terminated | French National Agency for Research on AIDS and Viral Hepatitis | 112 | 2003-11-01 | 2005-11-15 |
| A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth HIV Infections, HIV-Associated Lipodystrophy Syndrome | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 450 | 2003-10-01 | 2014-01-07 | |
| Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients nucleoside analogue sparing HAART regimen - HIV-Associated Lipodystrophy Syndrome | Phase 4 | Unknown | Danish HIV Research Group | 100 | 2003-06-01 | 2006-03-14 |
| HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) Lamivudine, Stavudine, Didanosine - HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease | Phase 4 | Completed | Kirby Institute | 80 | 2003-02-01 | 2012-04-12 |
Showing 20 of 25. Sign in to see all of them.
HIV Infections (15) · Lipodystrophy (9) · Acquired Immunodeficiency Syndrome (2) · Body Weight Changes (2) · Hypercholesterolemia (2) · Metabolic Syndrome (2) · Bone Diseases, Metabolic (1) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Dwarfism, Pituitary (1) · Dyslipidemias (1) · Fatty Liver (1) · Insulin Resistance (1) · Liver Cirrhosis (1)
Blood-Borne Infections (25) · Communicable Diseases (25) · Genital Diseases (25) · Immune System Diseases (25) · Immunologic Deficiency Syndromes (25) · Infections (25) · Lentivirus Infections (25) · Lipid Metabolism Disorders (25) · Metabolic Diseases (25) · Nutritional and Metabolic Diseases (25) · RNA Virus Infections (25) · Retroviridae Infections (25) · Sexually Transmitted Diseases (25) · Sexually Transmitted Diseases, Viral (25) · Skin Diseases (25)
Lamivudine (3) · Ritonavir (3) · Zidovudine (3) · Nevirapine (2) · Protease Inhibitors (2) · Tenofovir (2) · abacavir (2) · tesamorelin (2) · Atazanavir Sulfate (1) · Cobicistat (1) · Darunavir (1) · Diagnostic Tests, Routine (1) · Didanosine (1) · Enfuvirtide (1) · Fibric Acids (1)
French National Agency for Research on AIDS and Viral Hepatitis (4) · Danish HIV Research Group (2) · Kirby Institute (2) · Theratechnologies (2) · Amsterdam UMC, location VUmc (1) · Assistance Publique - Hôpitaux de Paris (1) · Augusta University (1) · Bristol-Myers Squibb (1) · Columbia University (1) · Hospital Clinic of Barcelona (1) · Hvidovre University Hospital (1) · NHS Lothian (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Universidade Federal do Rio Grande do Norte (1) · University of Novi Sad (1)
United States (9) · France (7) · Spain (4) · Denmark (3) · United Kingdom (3) · Australia (2) · Canada (2) · Belgium (1) · Brazil (1) · Finland (1) · Germany (1) · Italy (1) · Mexico (1) · Netherlands (1) · Poland (1)
Dominique Costagliola (3) · Ann-Brit E Hansen, M.D. (2) · Court Pedersen, Professor (2) · Jan Gerstoft, M.D., DMSc (2) · Abhimanyu Garg, M.D. (1) · Alex Laursen, D.M., DMSc (1) · Alex Laursen, M.D., DMSc (1) · Andrew Carr, A/Prof (1) · Andrew D Carr, MD (1) · Christophe Piketty (1) · Claudine Duvivier, MD (1) · David A Cooper, MD (1) · Grace Aldrovandi, MD (1)
PMID 18389900, PMID 18641035, PMID 19275490, PMID 19363330, PMID 19424051, PMID 19479079, PMID 19487903, PMID 19898246, PMID 20101189, PMID 20168204, PMID 20554713, PMID 22153841, PMID 22495074, PMID 23432777, PMID 23593417, PMID 23824675, PMID 25536669, PMID 28399815, PMID 28832410, PMID 34630129
R01DK065515 (1), R01DK110771 (1), R01HL065953 (1)